Literature DB >> 23781965

Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.

Joshua Burns1, Manoj Menezes, Richard S Finkel, Tim Estilow, Isabella Moroni, Emanuela Pagliano, Matilde Laurá, Francesco Muntoni, David N Herrmann, Kate Eichinger, Rosemary Shy, Davide Pareyson, Mary M Reilly, Michael E Shy.   

Abstract

Long-term studies of Charcot-Marie-Tooth (CMT) disease across the entire lifespan require stable endpoints that measure the same underlying construct (e.g., disability). The aim of this study was to assess the relationship between the CMT Pediatric Scale (CMTPedS) and the adult CMT Neuropathy Score (CMTNSv2) in 203 children, adolescents, and young adults with CMT. There was a moderate curvilinear correlation between the CMTPedS and the CMTNSv2 (Spearman's rho ρ = 0.716, p < 0.0001), although there appears to be a floor effect of the CMTNSv2 in patients with a milder CMT phenotype. Univariate analyses indicate that the relationship between the CMTPedS and CMTNSv2 scores improves with worsening disease severity and advancing age. Although one universal scale throughout life would be ideal, our data supports the transition from the CMTPedS in childhood to the CMTNSv2 in adulthood as a continuum of measuring lifelong disability in patients with CMT.
© 2013 Peripheral Nerve Society.

Entities:  

Mesh:

Year:  2013        PMID: 23781965      PMCID: PMC3714225          DOI: 10.1111/jns5.12024

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  10 in total

1.  Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease.

Authors:  Jana Haberlová; Pavel Seeman
Journal:  Pediatr Neurol       Date:  2010-12       Impact factor: 3.372

2.  Genetic and clinical aspects of Charcot-Marie-Tooth's disease.

Authors:  H Skre
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

3.  Total neuropathy score: validation and reliability study.

Authors:  D R Cornblath; V Chaudhry; K Carter; D Lee; M Seysedadr; M Miernicki; T Joh
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

4.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

Authors:  Joshua Burns; Robert Ouvrier; Tim Estilow; Rosemary Shy; Matilde Laurá; Julie F Pallant; Monkol Lek; Francesco Muntoni; Mary M Reilly; Davide Pareyson; Gyula Acsadi; Michael E Shy; Richard S Finkel
Journal:  Ann Neurol       Date:  2012-05       Impact factor: 10.422

6.  Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Joëlle Micallef; Shahram Attarian; Odile Dubourg; Pierre-Marie Gonnaud; Jean-Yves Hogrel; Tanya Stojkovic; Rafaelle Bernard; Elisabeth Jouve; Severine Pitel; Francois Vacherot; Jean-Francois Remec; Laurent Jomir; Eric Azabou; Mahmoud Al-Moussawi; Marie-Noelle Lefebvre; Laurence Attolini; Sadek Yaici; Daniel Tanesse; Michel Fontes; Jean Pouget; Olivier Blin
Journal:  Lancet Neurol       Date:  2009-10-07       Impact factor: 44.182

Review 7.  Diagnosis and new treatments in genetic neuropathies.

Authors:  M M Reilly; M E Shy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12       Impact factor: 10.154

8.  Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.

Authors:  Emanuela Pagliano; Isabella Moroni; Giovanni Baranello; Anita Magro; Alessia Marchi; Sara Bulgheroni; Maurizio Ferrarin; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

9.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

10.  Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Authors:  Davide Pareyson; Mary M Reilly; Angelo Schenone; Gian Maria Fabrizi; Tiziana Cavallaro; Lucio Santoro; Giuseppe Vita; Aldo Quattrone; Luca Padua; Franco Gemignani; Francesco Visioli; Matilde Laurà; Davide Radice; Daniela Calabrese; Richard A C Hughes; Alessandra Solari
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

  10 in total
  8 in total

Review 1.  Vincristine-induced peripheral neuropathy in pediatric cancer patients.

Authors:  Erika Mora; Ellen M Lavoie Smith; Clare Donohoe; Daniel L Hertz
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

2.  Coexistence of a T118M PMP22 missense mutation and chromosome 17 (17p11.2-p12) deletion.

Authors:  Nivedita U Jerath; John Kamholz; Tiffany Grider; Amy Harper; Andrea Swenson; Michael E Shy
Journal:  Muscle Nerve       Date:  2015-06-19       Impact factor: 3.217

3.  Translation and cross-cultural adaptation of the Charcot-Marie-Tooth disease Pediatric Scale to Brazilian Portuguese and determination of its measurement properties.

Authors:  Karoliny Lisandra Teixeira Cruz; Ana Cristina Resende Camargos; Juliana Cardoso; Cyntia Rogean de Jesus Alves de Baptista; Aline Duprat Ramos; Ana Claudia Mattiello-Sverzut; Joshua Burns; Hércules Ribeiro Leite
Journal:  Braz J Phys Ther       Date:  2020-08-07       Impact factor: 3.377

4.  A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.

Authors:  Wenjia Wang; Mickaël Guedj; Viviane Bertrand; Julie Foucquier; Elisabeth Jouve; Daniel Commenges; Cécile Proust-Lima; Niall P Murphy; Olivier Blin; Laurent Magy; Daniel Cohen; Shahram Attarian
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

5.  Case series: Childhood Charcot-Marie-Tooth: Predominance of axonal subtype.

Authors:  Apirada Thongsing; Theeraphong Pho-Iam; Chanin Limwongse; Surachai Likasitwattanakul; Oranee Sanmaneechai
Journal:  eNeurologicalSci       Date:  2019-07-25

6.  Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.

Authors:  Kayla M D Cornett; Manoj P Menezes; Paula Bray; Mark Halaki; Rosemary R Shy; Sabrina W Yum; Timothy Estilow; Isabella Moroni; Maria Foscan; Emanuela Pagliano; Davide Pareyson; Matilde Laurá; Trupti Bhandari; Francesco Muntoni; Mary M Reilly; Richard S Finkel; Janet Sowden; Katy J Eichinger; David N Herrmann; Michael E Shy; Joshua Burns
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

7.  Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS.

Authors:  Kayla M D Cornett; Manoj P Menezes; Paula Bray; Rosemary R Shy; Isabella Moroni; Emanuela Pagliano; Davide Pareyson; Tim Estilow; Sabrina W Yum; Trupti Bhandari; Francesco Muntoni; Matilde Laura; Mary M Reilly; Richard S Finkel; Katy J Eichinger; David N Herrmann; Michael E Shy; Joshua Burns
Journal:  Ann Clin Transl Neurol       Date:  2020-08-06       Impact factor: 4.511

8.  Characterizing postural oscillation in children and adolescents with hereditary sensorimotor neuropathy.

Authors:  Cyntia Rogean de Jesus Alves de Baptista; Adriana Nascimento-Elias; Tenysson Will Lemos; Beatriz Garcia; Paula Domingues Calori; Ana Claudia Mattiello-Sverzut
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.